Mehul Bhatt*, Hansal Desai
School of Pharmacy, Indrashil University, Rajpur, Kadi - 382740, Gujarat, India.
*Corresponding Author E-mail: mkb_0999@yahoo.co.in
ABSTRACT:
The therapeutic potential of focusing on the gut microbiota to enhance medication effectiveness and customize care is examined in this review. A promising avenue for contemporary medicine is the modulation of this microbial environment, given the mounting data that links the microbiome to human health, illness development, and treatment response. The composition of the microbiota, its function in drug metabolism, and its association with a range of physiological and pathological conditions are all critically examined in this article. Probiotics, prebiotics, postbiotics, fecal microbiota transplantation, modified microorganisms, and targeted delivery methods are among the well-known and recently developed microbiota-modulating techniques that are assessed. Although these methods have the potential to provide safer and more individualized treatments, issues such as standardization, regulatory uncertainty, and inter-individual variability still persist. It is anticipated that future developments in AI and multi-omics technology will deepen our knowledge and facilitate the application of microbiome-based precision medicine in clinical settings. Major Findings: The gut microbiota has a major impact on pharmacokinetics, pharmacodynamics, toxicity, and drug efficacy. Numerous illnesses, such as neurological, immunological, metabolic, and cancer-related disorders, have been linked to dysbiosis. Drug responsiveness can be improved and microbial equilibrium restored through precise microbiome modification. Furthermore, interactions between drugs and microbiota are reciprocal; drugs can alter the composition of microbes, and microbial enzymes can modify the effects of drugs.
KEYWORDS: Gut microbiota, Drug metabolism, Pharmacomicrobiomics, Personalized medicine, Microbiome–drug interactions.
INTRODUCTION:
Human Microbiota and Microbiome:
The diverse group of bacteria that live on the skin, in the mouth, respiratory system, and gastrointestinal tract is known as the human microbiota. The gut microbiota is the most active and dense. The aggregate genomes of these microorganisms are referred to as the microbiome. The gut microbiota is a promising area of study in pharmacology to enhance therapies and lessen adverse effects as advances in sequencing have demonstrated its critical role in host physiology and its impact on medication metabolism, efficacy, and safety.
Importance of Gut Microbiota in Health:
By facilitating digestion, generating vitamins, controlling immunity, and defending against infections, gut bacteria promote health. Short-chain fatty acids, which are produced during the fermentation of indigestible foods, supply energy and regulate immunological function. Drug metabolism is impacted by dysbiosis, an imbalance in gut bacteria, which is connected to metabolic, neurological, gastrointestinal, and cancer-related problems. This emphasizes the significance of microbiome-informed treatments1.
Rationale for Targeting Gut Microbiota in Drug Therapy:
The gut microbiota is a growing target for therapeutic intervention because of its significant involvement in both health and disease. Modulating gut microbial makeup can boost therapeutic efficacy, reduce side effects, and restore microbial equilibrium2,3. In diseases like inflammatory bowel disease and liver illnesses, dysbiosis can be corrected with the use of antibiotics and other drugs. Microbiota-modulating potential for repurposing is demonstrated by several FDA-approved medications4.
This overview looks at the makeup and roles of gut microorganisms, how they are linked to illness, and how they are currently being modulated5. New therapeutic medicines and individualized treatments may result from an understanding of signaling molecules originating from microbes. Drug-microbe interactions are complicated, which presents safety and efficacy issues despite the potential of microbiota-targeted treatments. Personalized, microbiome-based medication has great potential in the future, according to ongoing studies6,7.
Taxonomic Overview:
The human gut hosts a dynamic and diverse microbiota, including trillions of bacteria, viruses, archaea, fungi, and protozoa, with bacteria being the most abundant and important. Firmicutes, such as Clostridium, Lactobacillus, Enterococcus, and Ruminococcus, help produce short-chain fatty acids and digest dietary fibers. Bacteroidetes (Bacteroides, Prevotella) degrade complex carbohydrates, while Actinobacteria like Bifidobacterium support immunity and mucosal health. Proteobacteria, including Salmonella and Escherichia, can be harmful when elevated, and Verrucomicrobia, such as Akkermansia muciniphila, support metabolic health. Gut composition is influenced by diet, age, genetics, environment, antibiotics, and health, yet healthy individuals maintain a functional "core microbiota8-12.
Role in Digestion, Immunity, and Metabolism:
By converting indigestible carbohydrates into short-chain fatty acids that sustain gut integrity and nourish colon cells, the gut microbiota plays a critical role non metabolism, immunity, and digestion. In addition to producing vital vitamins like K, biotin, folate, and B-complex vitamins, bacteria like Bacteroides thetaiotaomicron aid in the breakdown of complex plant fibers. By creating Peyer's patches, boosting IgA synthesis, and halting the growth of dangerous pathogens, gut microorganisms enhance immunity. By improving energy extraction, controlling fat storage, and altering bile acids, they also have an impact on metabolism. While dysbiosis contributes to many chronic diseases, gut bacteria maintain barrier integrity, alter immune responses, and influence mood and gene expression through ongoing molecular signaling13-18.
Function of Gut Microbiota:
Since the majority of host-microbe interactions are now recognized to be neutral or advantageous, the conventional view that all microorganisms are dangerous has changed19-22. Digestion, immunological regulation, vitamin synthesis, energy extraction, and epithelial growth are all significantly impacted by gut bacteria. Microbes play a crucial role in the metabolism of complex polysaccharides, as evidenced by the higher energy requirements of germ-free (GF) mice. Numerous enzymes found in species like Bacteroides thetaiotaomicron break down carbs to produce short-chain fatty acids, which are vital for gut health23,24. GF mice exhibit decreased adiposity while consuming more food, indicating that microbiota also affects fat storage25. Intestinal bacteria produce a variety of vitamins, including vitamin K and B vitamins. Immune and vascular development, which are compromised in GF animals, are supported and colonization resistance is strengthened by gut flora. The integrity of the epithelial barrier depends on commensal bacteria' low-level TLR signaling26-30.
Gut Microbiota in Disease Pathophysiology:
Gastrointestinal Disorders (IBS, IBD):
The bacteria in the human gut are very important for keeping the immune system in check, balancing metabolism, and maintaining a healthy intestine. More and more, people are realizing that when the balance of gut bacteria is disrupted, it can lead to problems in the digestive system, like inflammatory bowel disease and irritable bowel syndrome.
Inflammatory Bowel Disease (IBD):
Immune dysregulation, genetics, environmental factors, and microbial imbalances combine intricately to cause inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC). In addition to increased opportunistic infections such as adherent-invasive Escherichia coli and Ruminococcus gnavus, IBD patients exhibit decreased helpful bacteria including Faecalibacterium prausnitzii and Roseburia spp. Reduced microbial diversity, changed Firmicutes/ Bacteroidetes ratios, a rise in pro-inflammatory taxa, increased intestinal permeability, and mucosal barrier dysfunction are all consequences of this dysbiosis. Butyrate-producing F. prausnitzii depletion exacerbates inflammation and increases the risk of illness recurrence. Changes in gut archaea, fungi, and viruses, such as decreases in Saccharomyces boulardii and Methanobrevibacter smithii and increases in Candida albicans and Caudovirales bacteriophages, are also linked to IBD31,32.
Irritable Bowel Syndrome (IBS):
Abdominal pain, bloating, and changes in bowel habits are common signs of IBS, a type of digestive system condition that is now being connected more closely to slight inflammation and changes in the bacteria found in the gut. People with IBS often have less variety in their gut bacteria, lower levels of certain short-chain fatty acids, and more gas-producing bacteria. These changes might lead to increased sensitivity in the abdomen and problems with digestion, even though their symptoms are not as serious as those seen in IBD. In cases where IBS follows an infection, changes in the gut bacteria and low-level immune responses in the gut lining are especially linked. Overall, these findings show how important gut bacteria are in the development of both IBD and IBS. They suggest that treatments aimed at improving gut bacteria, such as fecal microbiota transplantation, probiotics, prebiotics, and synbiotics, could help restore balance and reduce symptoms33.
Metabolic Disorders (Obesity, Type 2 Diabetes):
The complex collection of bacteria known as the gut microbiota is essential for immunological control, metabolism, and nutritional absorption; dysbiosis is associated with type 2 diabetes and obesity. Inflammation and insulin resistance are brought on by a decrease in microbial diversity, an increase in the Firmicutes/Bacteroidetes ratio, and an increase in Gram-negative bacteria that produce lipopolysaccharide (LPS). Metabolism is further disrupted by decreased synthesis of short-chain fatty acids (SCFA), particularly from Faecalibacterium prausnitzii and Eubacterium rectale. Beneficial species, including Akkermansia muciniphila and Roseburia, decrease in type 2 diabetes, weakening the intestinal barrier and exacerbating inflammation. Probiotics, prebiotics, synbiotics, and fecal microbiota transplantation are examples of treatments that can increase insulin sensitivity, lower inflammation, and restore equilibrium34-38.
Neurological Disorders (Gut–Brain Axis, Parkinson’s, Depression):
The gut-brain connection is a two-way system that links the brain and the gut bacteria. This connection has a big effect on brain health. More and more studies show that changes in gut bacteria may play a role in the beginning and progress of mental health issues and brain diseases, like major depression and Parkinson’s disease. This connection is called the Microbiota-Gut-Brain Axis. It includes the ways gut bacteria affect the brain through the immune system, nervous system, and hormones. Bacteria in the colon make different chemicals that affect the brain, such as short-chain fatty acids and brain chemicals like serotonin, dopamine, norepinephrine, and GABA. These chemicals can reach the brain directly by using the vagus nerve or by moving through the blood-brain barrier. They can also influence the brain indirectly by changing how the body fights infections and by causing inflammation in the whole body. When the gut bacteria are out of balance, it can cause a condition called "leaky gut38. This happens when the tight connections between cells in the gut wall are damaged, allowing harmful substances like lipopolysaccharide and other bacteria parts to enter the bloodstream. This leads to brain inflammation, continued immune reactions, and overactive microglia, which are signs of several brain diseases39.
Parkinson’s Disease (PD):
The makeup of the gut microbiota varies significantly in PD patients, with pro-inflammatory bacteria (like Proteobacteria) being more abundant and beneficial taxa like Prevotella, Bifidobacterium, and Faecalibacterium prausnitzii being less prevalent. Reduced SCFA synthesis, compromised gut barrier function, and systemic inflammation are all associated with these changes. The buildup of α-synuclein in enteric neurons, which may be facilitated by microbial dysbiosis, is one theory about the pathophysiology of Parkinson's disease. Neurodegeneration may be brought on by this misfolded protein ascending to the central nervous system through the vagus nerve. Furthermore, alterations in the microbial metabolism of dopamine precursors tyrosine and phenylalanine may impact cerebral dopamine synthesis, and specific gut microorganisms may alter dopaminergic pathways40.
Major Depressive Disorder (MDD):
Major depressive disorder (MDD) is associated with a decrease in anti-inflammatory bacteria such as Lactobacillus, Bifidobacterium, and Faecalibacterium, and an increase in Gram-negative LPS-producing bacteria that promote neuroinflammation and systemic inflammation. The kynurenine-serotonin balance may be shifted toward neurotoxicity and mood dysregulation as a result of this imbalance, which may also affect neurogenesis, neurotransmitter function, and tryptophan metabolism. Brain-derived neurotrophic factor (BDNF) expression and neuroplasticity are both decreased in MDD patients with lower short-chain fatty acid (SCFA) levels. Additionally, through the creation of neurotransmitters and neuromodulators, such as GABA, as well as through vagal and immunological signaling pathways, gut microbes affect mood and cognition41.
Autoimmune and Allergic Diseases:
Changes in gut microbiota are linked to autoimmune conditions include rheumatoid arthritis, multiple sclerosis, type 1 diabetes, systemic lupus erythematosus, celiac disease, Sjögren's syndrome, Graves' disease, and Hashimoto's thyroiditis. Patients frequently exhibit decreased microbial diversity, more dangerous taxa like Clostridium, Proteobacteria, and Prevotella, and less good bacteria like Bifidobacterium, Lactobacillus, and Faecalibacterium prausnitzii. Immune dysregulation, systemic inflammation, and increased gut permeability are all consequences of dysbiosis. Disease is made worse by certain microbial changes, such as enhanced Klebsiella in lupus or Porphyromonas gingivalis translocation in rheumatoid arthritis. Studies on fecal microbiota transplantation emphasize the causative role of microbiota and its significance in autoimmune development and treatment42.
Allergic Disorders:
Early-life microbial imbalances have also been linked to allergic disorders such food allergies, dermatitis, and asthma, though these topics are not as well covered in the article. immunological tolerance may be compromised by decreased microbial diversity and delayed colonization with advantageous commensals, which would tilt immunological responses in favor of Th2-mediated allergic inflammation. According to the "hygiene hypothesis" and its microbial extension, healthy immune development requires early exposure to a variety of bacteria43.
Role of Fecal Microbiota Transplantation (FMT):
In autoimmune illnesses, FMT has shown promise as a therapeutic approach to control immune responses and restore gut eubiosis. FMT has been shown in clinical and experimental research to reduce the severity of disease, balance the microbial makeup, and affect immune cell populations (e.g., Tregs, Th17). To prove its effectiveness and safety in extraintestinal autoimmune disorders, more controlled trials are required, as results vary by disease and donor 44.
Cardiovascular Disorders:
According to recent research, the pathogenesis of cardiovascular diseases (CVD), including atherosclerosis, hypertension, heart failure, and myocardial infarction, is significantly influenced by the gut bacteria. Numerous cardiovascular disorders are rooted in vascular dysfunction, metabolic dysregulation, and systemic inflammation, all of which have been linked to gut dysbiosis, a microbial imbalance (Figure 1).
Figure. 1 Microbiological metabolite. Illustration of the several microbial metabolites that set off particular pathophysiological processes in the emergence of cardiovascular disorders45
Atherosclerosis and Dysbiosis:
Lipid buildup and persistent inflammation in the artery walls are hallmarks of atherosclerosis. This process is facilitated by gut dysbiosis through multiple mechanisms:
Bacterial metabolites like trimethylamine-N-oxide (TMAO), which is produced from dietary choline and carnitine, increase cholesterol accumulation, inhibit reverse cholesterol transport, and promote vascular inflammation and platelet aggregation. • Increased gut permeability permits microbial products like lipopolysaccharide (LPS) and peptidoglycan (PG) to translocate into the bloodstream, activating toll-like receptors (TLRs) on immune cells and promoting atherogenesis (Figure 2&3).
Figure 2. gut feeling. An illustration of the possible connection between heart failure and dysbiosis45
Figure 3. theory of leaky gut. A simplified visual representation of the possible connection between tight junction disruption, inflammation, and dysbiosis45
Short-chain fatty acids (SCFAs) like acetate, butyrate, and propionate are produced by gut bacteria and affect blood pressure by acting on G-protein-coupled receptors (GPR41, GPR43) to control renin release and vascular tone. Reduced SCFA-producing bacteria and an elevated Firmicutes/Bacteroidetes ratio are associated with hypertension; oxidized LDL and inflammation further harm blood vessels. Reduced cardiac output and congestion in heart failure lead to gut barrier dysfunction, which makes it possible for endotoxins like LPS to produce systemic inflammation. Poorer outcomes are predicted by elevated TMAO levels. Microbial DNA found in infarcted tissue and atherosclerotic plaques may play a part in myocardial infarction. Interventions that enhance gut microbial diversity, SCFA production, and cardiovascular health include high-fiber or Mediterranean diets, probiotics, prebiotics, postbiotics, TMAO-lowering medications, fecal microbiota transplantation (FMT), and exercise45.
Cancer (Colorectal, Liver):
Dysbiosis, or an imbalance in the gut microbiota, is increasingly linked to digestive diseases like as colorectal and liver cancer. The gut microbiota is vital for immunity, metabolism, and intestinal health. Patients with colorectal cancer (CRC) often show reduced microbial diversity and higher levels of pathogenic bacteria such as Escherichia coli, Bacteroides fragilis, and Clostridium nucleatum. These bacteria cause DNA damage through toxins like colibactin, weaken the gut barrier by decreasing beneficial bacteria like Bifidobacterium and Lactobacillus, and ultimately increase permeability and immune activation.
In addition, harmful substances made by gut bacteria, like lipopolysaccharides (LPS) and secondary bile acids, can increase oxidative stress and cause changes in gene activity, making cancer more likely (Figure 4).
Figure 4. Suggested roles of the gut microbiota in the development of colon cancer5.
Gastric and Hepatobiliary Cancers:
Although the article's primary focus is on colorectal and stomach cancers, microbiota-mediated pathways allow for pertinent implications for liver cancer as well. Gut dysbiosis often coexists with chronic liver illnesses such cirrhosis and hepatitis, which are common preludes to hepatocellular carcinoma (HCC). Increased intestinal permeability facilitates the entry of microbial endotoxins, such as LPS, into the portal circulation, which leads to fibrosis, inflammation, and ultimately the development of cancer. Although not thoroughly discussed in this paper, comparable processes in illnesses of the gut-liver axis highlight the part that microbial imbalance plays in the pathogenesis of liver cancer and call for more research.
Therapeutic and Preventive Perspectives:
New treatments that try to change the bacteria in the gut to help fight colorectal cancer include probiotics, prebiotics, changes in diet, and fecal microbiota transplantation (FMT). Certain probiotic bacteria, such as Lactobacillus rhamnosus and Bifidobacterium longum, have shown abilities to reduce inflammation and stop cancer cells from growing in early studies. Also, eating more fiber can increase the production of short-chain fatty acids, especially butyrate, which might help prevent colorectal cancer by killing cancer cells and helping the lining of the gut to heal. Researchers are also looking at certain gut bacteria, like C. nucleatum found in the stool, as possible early signs of cancer that can be detected without invasive tests46.
Pharmacological Modulation of Gut Microbiota:
Lactobacillus, Bifidobacterium, and Akkermansia muciniphila are examples of probiotics, which are good live microorganisms that improve immunity, maintain the integrity of the gut barrier, restore microbial balance, and create SCFAs that are helpful in illnesses including IBD, metabolic disorders, and antibiotic-associated diarrhea. These beneficial bacteria are preferentially nourished by prebiotics such as inulin, resistant starch, GOS, FOS, and polyphenols, which enhance the generation of SCFA, the absorption of minerals, and the regulation of metabolism and inflammation.
Despite formulation issues, synbiotics offer therapeutic promise for allergies, obesity, and liver illnesses by combining prebiotics and probiotics to promote microbial diversity, strengthen gut barrier function, and modify immune. In addition to promoting immunity and gut integrity, postbiotics—non-living microbial metabolites such SCFAs, exopolysaccharides, and lysates—offer improved safety and stability, with compounds like OM-85 BV lowering respiratory infections. Microbiota-protective techniques are crucial because, although antibiotics treat infections, they can also upset the microbial balance, decrease good bacteria, change metabolism, and promote pathogen overgrowth, raising dangers like C. difficile infection and metabolic or autoimmune disorders.
Microbiota-Targeted Small Molecules:
A new class of medicines called microbiota-targeted small molecules aims to alter the makeup or activity of microorganisms. These include quorum sensing inhibitors to limit pathogenic behavior, bile acid modulators to change microbial ecology, SCFA mimetics to sustain the barrier, and TMAO (Trimethylamine N-oxide) inhibitors to lower cardiovascular risk. This also includes probiotics that have been engineered to provide medicinal substances. A promising area of precision microbiome-based therapies is represented by these methods47 (Figure 5).
Figure 5. illnesses linked to gut pathobionts. UC stands for ulcerative colitis; CD for Crohn's disease; and CRC for colorectal cancer47.
Drug–Microbiota Interactions:
Microbiota-Mediated Drug Metabolism:
A key idea in pharmacomicrobiomics is that gut microbes can enzymatically change the toxicity, bioavailability, and therapeutic effects of medications taken orally. Gut microorganisms like Clostridium species and Bacteroides dorei metabolize more than 66% of popular oral medications, affecting outcomes like brivudine-related hepatotoxicity or early levodopa degradation.
Impact of Drugs on Microbiota Composition:
The diversity and quantity of gut microbes are dramatically altered by a number of non-antibiotic medications, such as PPIs, metformin, laxatives, statins, and antidepressants. Up to 24% of human medications have antimicrobial-like effects. These alterations, such as PPI-induced overgrowth of oral bacteria or metformin-driven SCFA-producing strains, may impact host defenses and cause gastrointestinal problems.
Pharmacokinetic and Pharmacodynamic Modifications:
Through microbial biotransformation, drug–microbiota interactions can modify drug absorption, metabolism, distribution, and excretion. The need to evaluate microbiome influences during medication development and therapy is highlighted by the possibility that such actions could either boost benefits (e.g., increased SCFA synthesis with metformin) or diminish drug effectiveness (e.g., lower levodopa bioavailability)47.
Clinical Relevance of Drug–Microbiota Interactions:
Novel Therapeutic Agents:
Definition and Concept:
Fecal Microbiota Transplantation (FMT) is a clinical procedure that involves transplanting fecal matter from a healthy donor to restore a balanced microbiota in the recipient's gastrointestinal tract. This method aims to restore eubiosis, the optimal state of microbial equilibrium that can occasionally be disrupted by disease, antibiotics, or environmental factors. MT provides a varied community of microorganisms that support immunity, digestion, and metabolic health. These microorganisms include bacteria, fungi, viruses, and archaea. Although new evidence points to wider uses, the FDA now approves it only for recurrent Clostridium difficile infections49.
Gastrointestinal Disorders (IBD, IBS):
Fecal Microbiota Transplantation (FMT) improves remission, intestinal barrier strength, and inflammation in Inflammatory Bowel Disease (IBD) by reducing pathogenic Escherichia coli and restoring good bacteria such as Faecalibacterium prausnitzii. FMT improves microbial variety, reduces gas-producing bacteria, and reduces bloating and abdominal pain in people with irritable bowel syndrome (IBS), particularly in cases of post-infectious IBS.
Metabolic Disorders (Obesity, Type 2 Diabetes):
In obesity and Type 2 Diabetes (T2D), FMT from lean, healthy donors enhances insulin sensitivity, reduces systemic inflammation, and boosts bacteria that produce short-chain fatty acids (SCFA), including Roseburia.
FMT improves glucose metabolism and overall metabolic control in people with type 2 diabetes by lowering toxic endotoxins and restoring the integrity of the intestinal barrier.
Neurological and Psychiatric Conditions (Parkinson’s Disease, Depression):
FMT may improve motor and gastrointestinal symptoms in Parkinson's disease (PD) by reducing inflammation and aberrant protein aggregation brought on by gut dysbiosis through modulation of the gut–brain axis.
By resetting neurochemical pathways, bacteria that produce serotonin and Gamma-Aminobutyric Acid (GABA) can assist improve mood management and cognitive performance in Major Depressive Disorder (MDD).
Autoimmune and Allergic Diseases:
FMT is increasingly being used to treat autoimmune conditions such as rheumatoid arthritis, systemic lupus erythematosus, and type 1 diabetes. These illnesses are linked to an excess of pathogenic bacteria and a deficiency of a variety of beneficial bacteria in the digestive tract. By increasing the activity of unique immune cells known as Tregs, reducing detrimental inflammatory signals, and restoring the body's proper microbial balance, FMT can be beneficial. FMT from healthy individuals can lessen the severity of many illnesses, according to animal studies. However, the effectiveness depends on the particular illness and how well the patient and donor match, necessitating customized approaches.
Cardiovascular Health:
By decreasing systemic inflammation, reestablishing microbial diversity, boosting SCFA production, and lowering Trimethylamine N-oxide (TMAO) levels associated with heart disease, FMT may minimize cardiovascular risk. According to preliminary studies, FMT can lower inflammatory biomarkers and enhance vascular function in diseases like atherosclerosis, heart failure (HF), and hypertension (HTN).
Cancer (Colorectal, Liver):
Colorectal cancer (CRC) is caused by dysbiosis, which increases immunological dysregulation, DNA damage, and chronic inflammation. However, FMT can aid by lowering pathogenic germs and boosting good bacteria that produce butyrate.
By restoring the gut–liver axis, FMT may strengthen the intestinal barrier, lessen gut-derived toxins, and minimize liver inflammation and fibrosis in hepatocellular carcinoma (HCC)49.
Genetically Engineered Microbiota:
Genetically Engineered Microbiota: Novel Therapeutic Approaches:
Gut microbes are altered by genetically modified microbiota to carry out specific therapeutic tasks such as immune regulation, metabolite synthesis, and dysbiosis correction. These technologies provide precise control over gut ecosystems through genetic engineering and synthetic biology, but they still encounter difficulties because of the complexity of the microbiome.
In Vitro Genome Engineering of Gut Commensals:
This technique uses instruments including CRISPR-Cas systems, suicide plasmids, integrative vectors, and transposons to alter gut bacteria in a lab setting. Overcoming bacterial defense mechanisms, choosing the best gene-expression components, and guaranteeing plasmid compatibility are all obstacles to the successful production of therapeutic strains.
In Situ Genome Engineering in the Intestinal Environment:
In situ engineering directly alters bacterial genomes inside the gut using approaches such as bacterial conjugation and engineered bacteriophages. Although promising for targeting uncultivable microbes, it faces limitations like low DNA-transfer efficiency, restricted host range, and difficulty achieving precise delivery.
High-Throughput Genome Engineering Techniques:
Targeted gene control and the creation of mutant libraries are made possible by high-throughput technologies such as SAGE, Tn-seq, CRISPRi, and MAGE, which enable simultaneous gene editing and analysis in gut bacteria. By facilitating concurrent investigations of gene function, regulation, and metabolic pathway optimization, these methods speed up discovery.
Applications in Disease Treatment:
With potential applications in autoimmune, infectious, metabolic, and cancer illnesses, engineered microbiota function as "living drugs" that generate therapeutic metabolites, degrade toxic substances, or boost immune responses. Benefits like lowering inflammation, eliminating infections, and enhancing immunotherapy results have been shown for modified strains of Bacteroides and E. coli.
Future Prospects and Challenges:
Effective DNA delivery into a variety of microorganisms, immunological responses, a lack of genetic tools, and regulatory issues are some of the main challenges. In order to develop standardized, secure, and modular therapeutic systems, future advancements depend on artificial intelligence, metagenomic mining, and phage engineering.
Bacteriophage Therapy:
Bacteriophage therapy offers a powerful answer to antibiotic resistance by employing viruses that selectively infect and destroy bacteria while retaining the normal microbiota. As demonstrated by the successful treatment of MDR Pseudomonas aeruginosa joint infections and ESBL-producing Klebsiella pneumoniae UTIs, highly specific lytic phages efficiently target MDR, XDR, and PDR infections, penetrate biofilms, and frequently operate in concert with antibiotics. Targeted delivery technologies, like liposomes, nanoparticles, and phage-antibiotic conjugates, improve accuracy and stability despite difficulties with standardization, dosage, immunological responses, and preventing horizontal gene transfer. Phages and improved carriers are positioned as precise, flexible solutions against resistant pathogens and microbiome-linked disorders thanks to stimuli-responsive systems activated by pH or bacterial enzymes50.
Gut Microbiota and Personalized Medicine:
Personalized medicine is greatly influenced by the gut microbiota, which affects immune responses, drug metabolism, and general health. Genetics, diet, lifestyle, and environment all contribute to an individual's microbial profile. Gut bacteria are crucial in the treatment of metabolic, immunological, and mental health conditions because they can change the efficacy of medications, impact immune homeostasis, and play a significant role in gut-brain communication. In conditions including diabetes, obesity, cancer, and inflammatory bowel disease, where some microorganisms may act as early indicators, their involvement is evident. Predicting illness risks and treatment outcomes is made easier by developments in computer techniques that integrate genetic, clinical, and microbiological data. Microbiome-based methods have great potential to improve diagnosis and customize treatment, despite ongoing issues with microbial complexity, data consistency, and privacy51.
Precision Therapies Guided by Microbiome Profiles:
Microbiome-Based Stratification of Patients:
By examining each person's distinct gut microbial makeup, which varies greatly due to genetics, nutrition, lifestyle, and environment, microbiome-based patient stratification customizes dietary and medicinal approaches53.
Microbiome Biomarkers for Drug Response:
By finding microbial patterns associated with treatment outcomes, microbiome-based biomarkers—particularly those originating from the gut—are increasingly being utilized to predict and track individual responses to therapy. Metagenomic advancements improve patient classification and treatment monitoring by revealing disease-specific signatures, such as higher Fusobacterium in colorectal cancer and decreased butyrate-producing bacteria in type 2 diabetes. Improved vaccination responses and better results in chemotherapy, radiation, and immunotherapy are closely linked to increased microbial diversity. Important taxa that improve therapeutic efficacy or lessen toxicity include Akkermansia muciniphila, Lactobacillus rhamnosus GG, and Clostridium butyricum. Microbiome-based biomarkers have great potential to improve precision medicine by predicting treatment response and reducing side effects, even though only around 2.6% of bacterial species are shared between humans and mice, necessitating human validation54-60.
Current Challenges and Limitations in Microbiome Research:
Inter-Individual Variability:
The high difference between people's gut microbe communities is a big challenge in microbiome studies. These differences come from many things like a person's age, genes, surroundings, diet, and use of antibiotics61. Because what works for one person might not work for another or could even be harmful, this makes it hard to create standard treatments based on the microbiome62. Also, since the microbiome changes over time due to things like environment or lifestyle, it's tough to know how treatments will affect someone in the long run63. The changing and unique nature of the microbiome shows that we need more exact methods instead of using the same solution for everyone64,65.
Regulatory and Safety Issues:
Probiotics, live biotherapeutics, and fecal microbiota transplantation (FMT) are examples of microbiome-based goods that are currently governed by a variety of frequently contradictory regulatory regimes66. These goods are categorized as pharmaceuticals or biologics in some areas and as dietary supplements in others, which results in inconsistent oversight67. Different jurisdictions may have different requirements for safety, effectiveness, and quality as a result of this discrepancy68. For clinical dependability and patient safety to be guaranteed, unambiguous, uniform regulatory pathways must be established. Rigorous preclinical testing, standardization of manufacturing processes, and post-marketing surveillance will be essential for the responsible clinical implementation of microbiome-targeted therapies69,70.
Lack of Standardization in Microbiome Research:
Lack of uniformity in data processing, analysis processes, sequencing techniques, and sample collection limits the repeatability of microbiome research. Results from different research may be inconsistent or contradictory due to variations in stool collecting methods, storage settings, sequencing platforms, and bioinformatics processes71. It is still challenging to convert research findings into trustworthy clinical advice in the absence of defined procedures and validated bioinformatics tools72. A crucial prerequisite for moving the science closer to therapeutic utility is the establishment of generally recognized techniques for microbiome collecting, sequencing, and data analysis73-75.
Translational and Commercial Barriers:
Many microbiome-based discoveries encounter obstacles when transitioning from the lab to clinical and commercial applications, even with encouraging preclinical results76. The difficulty of building scalable production for microbial products, the limited predictive power of animal models, and the difficulty of demonstrating a causal relationship between microbial composition and disease are examples of translational hurdles. Furthermore, because microbiome-based treatments are customized, they frequently have significant development and implementation costs, which may prevent underprivileged populations from accessing them77,78. It will take interdisciplinary cooperation, clear regulations, and creative delivery and commercialization techniques to overcome these obstacles79,80.
FUTURE PERSPECTIVES:
Multi-omics Approaches:
Metagenomics, metabolomics, proteomics, and transcriptomics are only a few of the multi-omics technologies that could transform microbiome research and its clinical uses81,82. These resources offer a thorough understanding of metabolic outputs, host-microbe interactions, and microbial activities83. Researchers can create highly customized profiles that guide disease risk, treatment targets, and tailored interventions by fusing multi-omics data with host genomic and clinical information84. It is anticipated that this systems-level strategy would improve precision diagnostics, forecast medication reactions, and make customized microbiome-modulating treatments possible85.
AI-Driven Systems Pharmacology and Microbiome-Integrated Drug Development:
Through the management of intricate datasets, the prediction of therapeutic responses, the identification of microbial biomarkers, and the optimization of microbiome-informed dosage, artificial intelligence and systems pharmacology are revolutionizing microbiome research86-88. Understanding antibiotic, immunotherapy, and cancer treatment outcomes is improved by integrating microbiome data into drug–host interaction models. Microbiota profiling is becoming crucial throughout the drug development process because gut bacteria have a significant impact on medication metabolism, toxicity, and efficacy89. Precision prebiotics and tailored probiotics are examples of safer, targeted co-therapies that will be made possible by incorporating metagenomics, metabolomics, and transcriptomics into clinical trials90. Global cooperation and extensive microbiome datasets will hasten routine clinical use and regulatory acceptability91,92.
DISCUSSION:
Digestion, metabolism, immunity, and even behavior depend on the gut microbiota, and problems like IBD, IBS, obesity, diabetes, cancer, neurological ailments, and autoimmune diseases are associated with its imbalance, or dysbiosis. Medications and gut bacteria have a reciprocal link since these germs also affect drug metabolism and treatment outcomes. Although individual reactions differ, therapeutic approaches like probiotics, prebiotics, synbiotics, postbiotics, FMT, synthetic microbes, targeted delivery systems, and phage therapy are intended to restore or alter microbial equilibrium. Patient stratification and therapy response prediction are being improved by developments in synthetic biology, nanotechnology, multi-omics, and artificial intelligence. Microbiome-informed precision medicine has great potential for individualized, secure, and successful treatment despite obstacles including inter-individual variability and regulatory limitations.
CONCLUSION:
The gut microbiota plays a critical role in personalized medicine by impacting drug absorption, metabolism, and treatment results. Probiotics, prebiotics, synbiotics, postbiotics, fecal microbiota transplantation, and genetically modified microorganisms are examples of therapies that provide new options for customized treatments for autoimmune, cardiovascular, neurodegenerative, metabolic, and cancerous diseases. Individual differences, inconsistent regulations, and technical constraints in microbial modulation are obstacles. Microbiome-informed precision medicine will be advanced, patient stratification will be optimized, and therapy outcomes will be predicted by combining pharmacology, microbiology, systems biology, artificial intelligence, multi-omics, and computational modeling.
CONFLICTS OF INTEREST:
No conflicts of interest are disclosed by the writers.
ACKNOWLEDGEMENT:
The authors are grateful to the library of the School of Pharmacy at Indrashil University in Rajpur, Kadi, Gujarat, for their important help in gathering the literature for this work.
AUTHOR CONTRIBUTION:
Writing, editing, proofreading, and thorough communication are all handled by Bhatt Mehul. After gathering information and reviewing the body of existing literature. Additionally, Images for the article are created by Desai Hansal.
1. Walsh J, Griffin BT, Clarke G, Hyland NP. Drug–gut microbiota interactions: implications for neuropharmacology. British Journal of Pharmacology. 2018 Dec; 175(24): 4415-29. doi:10.1111/bph.14366
2. Di Vincenzo F, Nicoletti A, Negri M, Vitale F, Zileri Dal Verme L, Gasbarrini A, et al. Gut Microbiota and Antibiotic Treatments for the Main Non-Oncologic Hepato-Biliary-Pancreatic Disorders. Antibiotics (Basel). 2023 Jun 17; 12(6): 1068. doi:10.3390/antibiotics12061068
3. Shanahan F. 99th Dahlem Conference on Infection, Inflammation and Chronic Inflammatory Disorders: Host–microbe interactions in the gut: target for drug therapy, opportunity for drug discovery. Clinical and Experimental Immunology. 2010 Apr; 160(1): 92-7. doi:10.1111/j.1365-2249.2010. 04135.x
4. Barone M, Rampelli S, Biagi E, Bertozzi SM, Falchi F, Cavalli A, et al. Searching for New Microbiome-Targeted Therapeutics through a Drug Repurposing Approach. Journal of Medicinal Chemistry. 2021 Dec 9; 64(23): 17277-17286. doi: 10.1021/acs.jmedchem.1c01333.
5. Maciel-Fiuza MF, Muller GC, Campos DMS, do Socorro Silva Costa P, Peruzzo J, Bonamigo RR, et al. Role of gut microbiota in infectious and inflammatory diseases. Frontiers in Microbiology. 2023 Mar 27; 14: 1098386. doi:10.3389/fmicb.2023.1098386.
6. Di Vincenzo F, Nicoletti A, Negri M, Vitale F, Zileri Dal Verme L, Gasbarrini A, et al. Gut Microbiota and Antibiotic Treatments for the Main Non-Oncologic Hepato-Biliary-Pancreatic Disorders. Antibiotics. 2023 Jun 1; 12(6): 1068. doi:10.3390/antibiotics12061068.
7. Walsh J, Griffin BT, Clarke G, Hyland NP. Drug–gut microbiota interactions: implications for neuropharmacology. British Journal of Pharmacology. 2018 Dec 1; 175(24): 4415–29. doi:10.1111/bph.14366.
8. Ting NL-N, Lau HC-H, Yu J. Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes. Gut. 2022 Jul; 71(7): 1412–25. doi:10.1136/gutjnl-2021-326264.
9. Mruk-Mazurkiewicz H, Kulaszyńska M, Jakubczyk K, Janda-Milczarek K, Czarnecka W, Rębacz-Maron E, et al. Clinical Relevance of Gut Microbiota Alterations under the Influence of Selected Drugs—Updated Review. Biomedicines. 2023 Mar 1; 11(3): 952. doi:10.3390/biomedicines11030952.
10. Gebrayel P, Nicco C, Al Khodor S, Bilinski J, Caselli E, Comelli EM, et al. Microbiota medicine: towards clinical revolution. Journal of Translational Medicine. 2022 Mar 7; 20(1): 111. doi:10.1186/s12967-022-03296-9.
11. García-Cabrerizo R, Barros-Santos T, Campos D, Cryan JF. The gut microbiota alone and in combination with a social stimulus regulates cocaine reward in the mouse. Brain, Behavior, and Immunity. 2022 Oct 1; 107: 286–91. doi: 10.1016/j.bbi.2022.10.020.
12. Marashi A, Hasany SA, Moein Moghimi S, Kiani R, Mehran Asl S, Alavi Dareghlou Y, et al. Targeting gut-microbiota for gastric cancer treatment: a systematic review. Frontiers in Medicine. 2024 Aug 2; 11: 1412709. doi:10.3389/fmed.2024.1412709.
13. Mousa SNM, Sarfraz M, Mousa WK. The Interplay between Gut Microbiota and Oral Medications and Its Impact on Advancing Precision Medicine. Metabolites. 2023 May 1;13(5):674. doi:10.3390/metabo13050674.
14. Ohkusa T, Nishikawa Y, Sato N. Gastrointestinal disorders and intestinal bacteria: Advances in research and applications in therapy. Frontiers in Medicine. 2023 Feb 7; 9: 935676. doi:10.3389/fmed.2022.935676.
15. Artusa V, Calabrone L, Mortara L, Peri F, Bruno A. Microbiota-Derived Natural Products Targeting Cancer Stem Cells: Inside the Gut Pharma Factory. International Journal of Molecular Sciences. 2023 Mar 1; 24(5): 4997. doi:10.3390/ijms24054997.
16. Drapkina OM, Yafarova AA, Kaburova AN, Kiselev AR. Targeting Gut Microbiota as a Novel Strategy for Prevention and Treatment of Hypertension, Atrial Fibrillation and Heart Failure: Current Knowledge and Future Perspectives. Biomedicines. 2022 Aug 1; 10(8): 2019. doi:10.3390/biomedicines10082019.
17. Degraeve AL, Haufroid V, Loriot A, Gatto L, Franeker Jan Andries V, Vereecke L, et al. Gut microbiome modulates tacrolimus pharmacokinetics through the transcriptional regulation of ABCB1. Microbiome. 2023 Jul 6; 11(1): 178. doi:10.1186/s40168-023-01578-y.
18. Flaig B, Garza R, Singh B, Hamamah S, Covasa M. Treatment of Dyslipidemia through Targeted Therapy of Gut Microbiota. Nutrients. 2023 Jan 1; 15(1): 228. doi:10.3390/nu15010228.
19. Conti G, D’Amico F, Fabbrini M, Brigidi P, Barone M, Turroni S. Pharmacomicrobiomics in Anticancer Therapies: Why the Gut Microbiota Should Be Pointed Out. Genes. 2022 Dec 24; 14(1): 55. doi:10.3390/genes14010055.
20. Kouidhi S, Zidi O, Belkhiria Z, Rais H, Ben Ayed F, Mosbah A, et al. Gut microbiota, an emergent target to shape the efficiency of cancer therapy. Exploration of Targeted Anti-Tumor Therapy. 2023 Apr 26; 4: 240–65. doi:10.37349/etat.2023.00069.
21. Pant A, Maiti TK, Mahajan D, Das B. Human Gut Microbiota and Drug Metabolism. Microbial Ecology. 2022 Jul 23; 86(1): 97–111. doi:10.1007/s00248-022-02081-x.
22. Yu W, Jiang Y-F, Xu H, Zhou Y-F. The Interaction of Gut Microbiota and Heart Failure with Preserved Ejection Fraction: From Mechanism to Potential Therapies. Advances in Cardiovascular Diseases.
23. Fan H, Sheng S, Zhang F. New hope for Parkinson’s disease treatment: Targeting gut microbiota. CNS Neuroscience & Therapeutics. 2022 Jul 13; 28(11): 1675–88. doi:10.1111/cns.13931.
24. Jia L, Huang S, Sun B, Shang Y, Zhu C. Pharmacomicrobiomics and type 2 diabetes mellitus: A novel perspective towards possible treatment. Frontiers in Endocrinology. 2023 Mar 23; 14: (article number). doi:10.3389/fendo.2023.109922
25. Singh T, Kaur G, Kaur A. Dysbiosis—An Etiological Factor for Cardiovascular Diseases and the Therapeutic Benefits of Gut Microflora. 2023 Apr 4; (2023):1–8. doi:10.1155/2023/7451554.
26. Forlano R, Sivakumar M, Mullish BH, Manousou P. Gut Microbiota—A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review. International Journal of Molecular Sciences. 2022 Jul 27; 23(15): 8307. doi:10.3390/ijms23158307.
27. Miftahussurur M, Freye R. Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism. The FASEB Journal. 2022 May 17; 36(6): e22468. doi:10.1096/fj.202201376RR.
28. Tong S, Zhang P, Cheng Q, Chen M, Chen X, Wang Z, et al. The role of gut microbiota in gout: Is gut microbiota a potential target for gout treatment. Frontiers in Cellular and Infection Microbiology. 2022 Nov 24; 12: (article number). doi:10.3389/fcimb.2022.102433.
29. Larabi AB, Masson HLP, Bäumler AJ. Bile acids as modulators of gut microbiota composition and function. Gut Microbes. 2023; 15(1): 2172671. doi:10.1080/19490976.2023.2172671.
30. Dikeocha IJ, Al-Kabsi AM, Miftahussurur M, Alshawsh MA. Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism. The FASEB Journal. 2022 May 17;36(6): e22468. doi:10.1096/fj.202201376RR.
31. Dikeocha IJ, Al-Kabsi AM, Miftahussurur M, Alshawsh MA. Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism. The FASEB Journal. 2022 May 17; 36(6): e22468. doi:10.1096/fj.202201376RR.
32. Wan Y, Zuo T. Interplays between drugs and the gut microbiome. Gastroenterology Report. 2022 Apr 8; 10: goac009. doi:10.1093/gastro/goac009.
33. Pandey H, Jain D, Tang DWT, Wong SH, Lal D. Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease. Intest Res. 2024 Jan; 22(1): 15–43. doi:10.5217/ir.2023.00080.
34. Chae WR. Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma. Journal of Translational Medicine. 2023 Mar 16; 21(1): 198. doi:10.1186/s12967-023-04042-5.
35. Liu B, Zhang L, Yang H, Zheng H, Liao X. Microbiota: A potential orchestrator of antidiabetic therapy. Frontiers in Endocrinology. 2023 Jan 27; 14: 109810. doi:10.3389/fendo.2023.109810.
36. Nishida A, Nishino K, Ohno M, Sakai K, Owaki Y, Noda Y, et al. Update on gut microbiota in gastrointestinal diseases. World Journal of Clinical Cases. 2022 Aug 6; 10(22): 7653–64. doi:10.12998/wjcc. v10.i22.7653.
37. Liu W, Luo Z, Zhou J, Sun B. Gut Microbiota and Antidiabetic Drugs: Perspectives of Personalized Treatment in Type 2 Diabetes Mellitus. Frontiers in Cellular and Infection Microbiology. 2022 May 31; 12: 931056. doi:10.3389/fcimb.2022.931056.
38. Del Chierico F, Rapini N, Deodati A, Matteoli MC, Cianfarani S, Putignani L. Pathophysiology of Type 1 Diabetes and Gut Microbiota Role. IJMS. 2022 Nov 24; 23(23): 14650. doi:10.3390/ijms232314650.
39. Liu W, Luo Z, Zhou J, Sun B. Gut Microbiota and Antidiabetic Drugs: Perspectives of Personalized Treatment in Type 2 Diabetes Mellitus. Frontiers in Cellular and Infection Microbiology. 2022 May 31; 12: 931056. doi:10.3389/fcimb.2022.931056.
40. Munshi R, Solanki S, Karande AA, Ranganathan P. Emerging role of gut microbiota dysbiosis in neuroinflammation and neurodegeneration. Frontiers in Neurology. 2023 May 15; 14: 1149618. doi:10.3389/fneur.2023.1149618.
41. Kim D-H. Gut Microbiota-Mediated Drug-Antibiotic Interactions. Drug Metabolism and Disposition. 2015 Oct 1; 43(10): 1581–9. doi: 10.1124/dmd.115.063867.
42. Westberg J, Keranda Kabupaten Bima J. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. Journal of Hematology & Oncology. 2022 Apr 29; 15(1). doi: 10.1186/s13045-022-01273-9.
43. Swanson HI. Drug Metabolism by the Host and Gut Microbiota: A Partnership or Rivalry? Drug Metabolism and Disposition. 2015 Oct 1; 43(10): 1499–504. doi: 10.1124/dmd.115.063867.
44. Belvoncikova P, Maronek M, Gardlik R. Gut Dysbiosis and Fecal Microbiota Transplantation in Autoimmune Diseases. International Journal of Molecular Sciences. 2022 Sep 14; 23(18): 10729. doi: 10.3390/ijms231810729.
45. Skok P, Skok K. Gut microbiota and the pathophysiology of cardiovascular disease. Archives of Medical Science. 2021. doi: 10.5114/aoms/127177
46. Chen J. The role of gut microbiota in digestive system cancers: mechanisms and potential therapeutic targets. Theoretical and Natural Science. 2024 Dec 12; 70(1): 62–7. doi: 10.54254/2753-8818/2024.18231.
47. Fan D, Hu J, Lin N. Effects of probiotics, prebiotics, synbiotics and postbiotics on pediatric asthma: a systematic review. Frontiers in Nutrition. 2025 Apr 25; 12. doi: 10.3389/fnut.2025.1586129.
48. Weersma RK, Zhernakova A, Fu J. Interaction between drugs and the gut microbiome. Gut. 2020 Aug; 69(8): 1510–9. doi: 10.1136/gutjnl-2019-320204.
49. Hamamah S, Gheorghita R, Lobiuc A, Sirbu IO, Covasa M. Fecal microbiota transplantation in non-communicable diseases: Recent advances and protocols. Frontiers in Medicine. 2022. doi: 10.3389/fmed.2022.1023456.
50. Chou S, Zhang S, Guo H, Chang Y-F, Zhao W, Mou X. Targeted Antimicrobial Agents as Potential Tools for Modulating the Gut Microbiome. Frontiers in Microbiology. 2022 Jul 7. doi: 10.3389/fmicb.2022.877129.
51. Siraj S. Role of Microbiome in Personalized Medicine. Precision Medicine Communications. 2023 Dec 31; 3(2): 79. doi: 10.1186/s44156-023-00013-3.
52. Lam KN, Alexander M, Turnbaugh PJ. Precision Medicine Goes Microscopic: Engineering the Microbiome to Improve Drug Outcomes. Cell Host & Microbe. 2019 Jul; 26(1): 22–34. DOI: 10.1016/j.chom.2019.06.004.
53. Liu Z, de Vries B, Gerritsen J, Smidt H, Zoetendal EG. Microbiome-based stratification to guide dietary interventions to improve human health. Nutrition Research. 2020 Oct; 82: 1–10. DOI: 10.1016/j.nutres.2020.06.002.
54. Gulliver EL, Young RB, Chonwerawong M, D’Adamo GL, Thomason T, Widdop JT, et al. Review article: the future of microbiome-based therapeutics. Aliment Pharmacol Ther. 2022 Jul; 56(2): 192–208. DOI: 10.1111/apt.17049.
55. Lee HL, Shen H, Hwang IY, Ling H, Yew WS, Lee YS, et al. Targeted Approaches for In Situ Gut Microbiome Manipulation. Genes. 2018 Jul 12; 9(7):351. DOI: 10.3390/genes9070351.
56. Lanthier N, Delzenne NM. Targeting the Gut Microbiome to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: Ready for Prime Time? Cells. 2022 Aug 31; 11(17): 2718. DOI: 10.3390/cells11172718.
57. Cryan JF, de Wit H. The gut microbiome in psychopharmacology and psychiatry. Psychopharmacology (Berl). 2019 May; 236(5): 1407–9. DOI: 10.1007/s00213-019-05288-y.
58. Ejtahed H-S, Soroush A, Angoorani P, Larijani B, Hasani-Ranjbar S. Gut Microbiota as a Target in the Pathogenesis of Metabolic Disorders: A New Approach to Novel Therapeutic Agents. Hormone and Metabolic Research. 2016 May 20; 48(6): 349–58. DOI: 10.1055/s-0042-107792.
59. Vich Vila A, Collij V, Sanna S, Sinha T, Imhann F, Bourgonje AR, et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nature Communications. 2020 Jan 17; 11(1): 362. DOI: 10.1038/s41467-019-14177-z.
60. Cani PD, Delzenne NM. The gut microbiome as therapeutic target. Pharmacology & Therapeutics. 2011; 130(2): 202–12. DOI: 10.1016/j.pharmthera.2011.01.008.
61. Sumit SD. Targeting the Microbiome: New Frontiers in Drug Development and Therapeutic Strategies. Scholar’s Digest: Journal of Pharmacology. 2025; 1(1): 56–75. Available at: https://scholarsdigest.org.in/index.php/sdjph/article/view/93
62. Feng W, Liu J, Ao H, Yue S, Peng C. Targeting gut microbiota for precision medicine: Focusing on the efficacy and toxicity of drugs. Theranostics. 2020; 10(24): 11278–11301. https://doi.org/10.7150/thno.47289.
63. Zhu LR, Li SS, Zheng WQ, Ni WJ, Cai M, Liu HP. Targeted modulation of gut microbiota by traditional Chinese medicine and natural products for liver disease therapy. Front Immunol. 2023; 14:1086078. https://doi.org/10.3389/fimmu.2023.1086078.
64. Izzo AA. Novel insights which may translate into treatments for irritable bowel syndrome. Front Pharmacol [Internet]. 2013 Dec 31; 4: 160. Available from: https://doi.org/10.3389/fphar.2013.00160.
65. Izzo AA, Capasso R, Aviello G, et al. Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br J Pharmacol. 2012 Jun; 166(4): 1444–60. Available from: https://doi.org/10.1111/j.1476-5381.2012.01879.x
66. Angelo A. Izzo, Izzo AA, Raffaele Capasso, Capasso R, Gabriella Aviello, Aviello G, et al. Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. British Journal of Pharmacology. 2012 Jun 1; 166(4): 1444–60. doi: 10.1111/j.1476-5381.2012. 01879.x
67. Suk KT, Kim DJ. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol [Internet]. 2019 Mar 4 [cited 2025 Jul 17];13(3):193–204.
68. Jia W, Li H, Zhao L, Nicholson JK. Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov [Internet]. 2008 Feb; 7(2): 123–9.
69. Zhu M, Liu X, Ye Y, Yan X, Cheng Y, Zhao L, et al. Gut microbiota: a novel therapeutic target for Parkinson’s disease. Front Immunol [Internet]. 2022 [cited 2025 Jul 17]; 13:937555.
70. Belizário JE, Faintuch J, Garay-Malpartida M. Gut Microbiome Dysbiosis and Immunometabolism: New Frontiers for Treatment of Metabolic Diseases. Mediators Inflamm [Internet]. 2018 Dec 9; 2018:2037838.
71. Zhao Q, Chen Y, Huang W, Zhou H, Zhang W. Drug-microbiota interactions: an emerging priority for precision medicine. Signal Transduction and Targeted Therapy. 2023; 8(1): 386. https://doi.org/10.1038/s41392-023-01597-2
72. Izzo AA, Coutts AA. Cannabinoids and the digestive tract. In: Handbook of Experimental Pharmacology. 2005; 168: 573–98. https://doi.org/10.1007/3-540-26573-2_21
73. Cani PD, Delzenne NM. The gut microbiome as therapeutic target. Pharmacology & Therapeutics. 2011; 130(2): 202–12. https://doi.org/10.1016/j.pharmthera.2011.01.012
74. Sumit SD. Targeting the Microbiome: New Frontiers in Drug Development and Therapeutic Strategies. Scholar’s Digest: Journal of Pharmacology. 2025; 1(1): 56–75. https://scholarsdigest.org.in/index.php/sdjph/article/view/93
75. Feng W, Liu J, Ao H, Yue S, Peng C. Targeting gut microbiota for precision medicine: Focusing on the efficacy and toxicity of drugs. Theranostics. 2020; 10(24): 11278–11301. https://doi.org/10.7150/thno.47289
76. Zhu LR, Li SS, Zheng WQ, Ni WJ, Cai M, Liu HP. Targeted modulation of gut microbiota by traditional Chinese medicine and natural products for liver disease therapy. Front Immunol. 2023;14:1086078. https://doi.org/10.3389/fimmu.2023.1086078
77. Izzo AA. Novel insights which may translate into treatments for irritable bowel syndrome. Front Pharmacol. 2013; 4: 160. https://doi.org/10.3389/fphar.2013.00160
78. Izzo AA, Capasso R, Aviello G, et al. Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br J Pharmacol. 2012; 166(4): 1444–60. https://doi.org/10.1111/j.1476-5381.2012.01879.x
79. Suk KT, Kim DJ. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2019; 13(3): 193–204. https://doi.org/10.1080/17474124.2019.1575244
80. Jia W, Li H, Zhao L, Nicholson JK. Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov. 2008;7(2):123–9. https://doi.org/10.1038/nrd2462
81. Zhu M, Liu X, Ye Y, Yan X, Cheng Y, Zhao L, et al. Gut microbiota: a novel therapeutic target for Parkinson’s disease. Front Immunol. 2022; 13: 937555. https://doi.org/10.3389/fimmu.2022.937555.
82. Izzo AA, Coutts AA. Cannabinoids and the digestive tract. Handb Exp Pharmacol. 2005; (168): 573–98. doi: 10.1007/3-540-26573-2_19.
83. Jia W, Li H, Zhao L, Nicholson JK. Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov. 2008 Feb;7(2):123–9. doi: 10.1038/nrd2505.
84. Karakan T. Gut microbiota modulation in cirrhosis: A new frontier in hepatology. Turk J Gastroenterol. 2014 May 21; 25(1): 126. doi: 10.5152/tjg.2014.0007.
85. Jia W, Li H, Zhao L, Nicholson JK. Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov. 2008; 7(2): 123–9. https://doi.org/10.1038/nrd2462
86. Karakan T. Gut microbiota modulation in cirrhosis: A new frontier in hepatology. Turk J Gastroenterol. 2014; 25(1): 126. doi: 10.5152/tjg.2014.0007.
87. Wu J, Singleton SS, Bhuiyan U, Krammer L, Mazumder R. Multi-omics approaches to studying gastrointestinal microbiome in the context of precision medicine and machine learning. Front Mol Biosci. 2024 Jan 19;10: 10.3389/fmolb.2023.1337373.
88. Chetty A, Blekhman R. Multi-omic approaches for host-microbiome data integration. Gut Microbes. 2024 Dec 31; 16(1): 10.1080/19490976.2023.2297860.
89. Logotheti M, Agioutantis P, Katsaounou P, Loutrari H. Microbiome Research and Multi-Omics Integration for Personalized Medicine in Asthma. J Pers Med. 2021 Dec 5; 11(12): 1299. doi: 10.3390/jpm11121299.
90. Zhang Y, Thomas JP, Korcsmaros T, Gul L. Integrating multi-omics to unravel host-microbiome interactions in inflammatory bowel disease. Cell Rep Med. 2024 Sep 17; 5(9): 101738. doi: 10.1016/j.xcrm.2024.101738.
91. Duan D, Wang M, Han J, Li M, Wang Z, Zhou S, et al. Advances in multi-omics integrated analysis methods based on the gut microbiome and their applications. Front Microbiol. 2025 Jan 3; 10.3389/fmicb.2024.1509117.
92. Kaur H, Kaur A, Singh M. Gut Microbiota in Drug Metabolism: A New Frontier in Precision Medicine. Int J Sci Res Eng Manag. 2025 May 8; 9(5): 1–9. doi: 10.55041/IJSREM47264.
|
Received on 20.11.2025 Revised on 14.01.2026 Accepted on 24.02.2026 Published on 21.04.2026 Available online from April 24, 2026 Res. J. Pharmacognosy and Phytochem. 2026; 18(2):169-181. DOI: 10.52711/0975-4385.2026.00024 ©A&V Publications All right reserved
|
|
|
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License. |
|